Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.
In 2009, the global outbreak of an influenza pandemic emphasized the need for an effective vaccine adjuvant. In this study, we examined the efficacy of poly-γ-glutamic acid/chitosan (PC) nanogel as an adjuvant for the influenza vaccine. PC nanogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity. Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologous and heterosubtypic [A/Philippines/2/82 (H3N2)] virus challenges. However, CD8+T cell-depleted mice displayed no protection against the heterosubtypic virus challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine. We also observed that using PC nanogel as a vaccine adjuvant had a dose-sparing effect and significantly enhanced the long-lasting protection of the pH1N1 vaccine. Together, these results suggest that PC nanogel is a promising vaccine adjuvant that could broadly prevent influenza virus infection.
Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Jihyun
J
Yang
Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.|Department of Molecular Biology and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, Republic of Korea.
Sang-Mu
SM
Shim
Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.|Department of Biotechnology, University of Science and Technology, Daejeon, Republic of Korea.
Thi Quyen
TQ
Nguyen
Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.|College of Medicine, Chungbuk National University, Cheongju, Republic of Korea.
Eun-Ha
EH
Kim
BioLeaders Corporation, Daejeon, Republic of Korea.
Kwang
K
Kim
Sungkyunkwan Advanced Institute of Nanotechnology (SAINT) and Department of Chemical Engineering, Sungkyunkwan University Suwon, Republic of Korea.
Yong Taik
YT
Lim
BioLeaders Corporation, Daejeon, Republic of Korea.|Department of Bio and Fermentation Convergence Technology, Kookmin University, Seoul, Republic of Korea.
Moon-Hee
MH
Sung
Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Richard
R
Webby
Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.|Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.|Department of Biotechnology, University of Science and Technology, Daejeon, Republic of Korea.
Haryoung
H
Poo
D000276:Adjuvants, Immunologic; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D048271:Chitosan / Q000031:analogs & derivatives* / Q000737:chemistry; D003429:Cross Reactions / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D005289:Ferrets; D015395:Histocompatibility Antigens Class I / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular; D000071497:Immunogenicity, Vaccine; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000737:chemistry / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control*; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000401:mortality / Q000517:prevention & control; D010588:Phagosomes / Q000378:metabolism; D011099:Polyglutamic Acid / Q000031:analogs & derivatives* / Q000737:chemistry
D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D015395:Histocompatibility Antigens Class I; D007252:Influenza Vaccines; C000594594:chitosan-poly(gamma-glutamic acid); D011099:Polyglutamic Acid; D048271:Chitosan